Quest Diagnostics (DGX)
Provides clinical testing, pathology, and laboratory services through a North American network.
$237.42
vs last close+2.66 (+1.13%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 95.74% | 105.67M shares | |
|---|---|---|---|
| 1,126 holders · as of Jun 30, 2026 | |||
| Insiders | 0.44% | 483.4K shares | |
| 19 holders · as of Sep 3, 2026 | |||
| Other | 3.82% | 4.22M shares | |
| remainder | |||
110.37M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
1,126 holders · 105.67M shares · 121 new positions · 553 increased · 354 reduced · 80 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.28M | 8.40% | +103.1K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 7.23M | 6.55% | +87.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 6.13M | 5.55% | +49.6K | Aug 13, 2026 |
| State Street Corp | 5.52M | 5.00% | +135.8K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 5.44M | 4.93% | −853.0K | Aug 14, 2026 |
| Boston Partners | 4.74M | 4.30% | +732.2K | Aug 4, 2026 |
| JPMorgan Chase & Co | 3.52M | 3.19% | −326.0K | Aug 12, 2026 |
| Geode Capital Management, LLC | 3.14M | 2.84% | +51.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.40% | 9.31M | 13G | Apr 17, 2025 |
| Vanguard Capital Management | 7.53% | 8.27M | 13G | Apr 30, 2026 |
| T. Rowe Price Associates, Inc. | 6.50% | 7.21M | 13G | Aug 14, 2025 |
| Vanguard Portfolio Management | 5.54% | 6.10M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | J. E. Davisdirector, officer: CEO and President | Sale | 10,000 | $242.72 | 122,423 |
| Aug 28, 2026 | Michael E. Prevoznikofficer: SVP & General Counsel | Sale · 3 lots | 22,677 | $243.11 | 37,557 |
| Jul 28, 2026 | Mark E. Delaneyofficer: SVP & Chief Commercial Officer | Sale | 1,600 | $235.18 | 10,335 |
| Jun 4, 2026 | Karthik Kuppusamyofficer: SVP, Clinical Solutions | Sale | 8,147 | $200.00 | 13,510 |
| Jun 1, 2026 | J. E. Davisdirector, officer: CEO and President | Sale | 10,000 | $194.14 | 132,423 |
| Mar 4, 2026 | Karthik Kuppusamyofficer: SVP, Clinical Solutions | Sale | 2,628 | $204.86 | 13,441 |
| Mar 5, 2026 | Patrick Plewmanofficer: SVP for Diagnostic Services | Sale | 2,855 | $206.21 | 15,198 |
| Mar 5, 2026 | Michael E. Prevoznikofficer: SVP & General Counsel | Sale | 3,878 | $206.21 | 37,557 |
| Mar 5, 2026 | Catherine T. Dohertyofficer: EVP, Regional Businesses | Sale | 5,558 | $206.21 | 67,122 |
| Mar 3, 2026 | Patrick Plewmanofficer: SVP for Diagnostic Services | Sale | 410 | $207.73 | 15,198 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Carol Devine Miller · WV01 | Sale | $15,001 – $50,000 | Spouse | Mar 10, 2025 | Aug 14, 2026 |
| Rep. Julie Johnson · TX32 | Sale | $1,001 – $15,000 | Joint | Oct 30, 2025 | Aug 6, 2026 |
| Sen. Alan Armstrong | Purchase | $1,001 – $15,000 | Joint | Mar 27, 2026 | Jul 21, 2026 |